Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.45 |
| ▸ | HTR1B | P28222 | 4/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapoxetine SCHEMBL9614075 | 0.90 | KMT2A (0.59) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9613796 | 0.89 | KMT2A (0.51) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9613710 | 0.88 | KMT2A (0.53) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9613924 | 0.86 | KMT2A (0.51) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9614065 | 0.84 | KMT2A (0.53) | KMT2AKDM4EALDH1A1HPGDATM | |
| Dapoxetine SCHEMBL9613718 | 0.84 | KMT2A (0.50) | KMT2AKDM4EALDH1A1HPGDATM | |
| Dapoxetine SCHEMBL28925361 | 0.84 | HTR1B (0.50) | KMT2AKDM4EALDH1A1HPGDHTR1B | |
| Dapoxetine SCHEMBL28759763 | 0.84 | HTR1B (0.52) | KMT2AKDM4EALDH1A1HTR1BCHRNB2 | |
| Dapoxetine SCHEMBL3672581 | 0.84 | HTR1B (0.57) | KMT2AHTR1BCHRNB2CHRNB4CHRNA3 | |
| Dapoxetine SCHEMBL3679561 | 0.84 | HTR1B (0.57) | KMT2AHTR1BCHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5135947-A | Treatment of depression, eating disorders, and alcoholism | ELI LILLY AND COMPANY (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0288188-B1 | 1-PHENYL-3-NAPHTHALENYLOXY-PROPANAMINES | ELI LILLY AND COMPANY (US) | 1991-10-16 | — | — | EP | disclosed |
| EP-0288188-A1 | 1-Phenyl-3-naphthalenyloxy-propanamines | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | disclosed |